Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer (Q37963231)

26 August 2017

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer (English)

1 reference

26 August 2017

1 reference

1 reference

1 reference

Jan Nyrop Jakobsen

1

1 reference

PubMed ID

22130585

26 August 2017

Jens Benn Sørensen

series ordinal

2

1 reference

26 August 2017

1 December 2011

1 reference

Cancer Chemotherapy and Pharmacology

26 August 2017

1 reference

26 August 2017

69

1 reference

26 August 2017

2

1 reference

26 August 2017

289-299

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1791-9

26 August 2017

0 references

cites work

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

21 January 2018

Lung cancer preneoplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Lung cancer * 9: Molecular biology of lung cancer: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Molecular genetics of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

EGFR FISH versus mutation: different tests, different end-points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

EGFR assays in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

A high frequency of sequence alterations is due to formalin fixation of archival specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Frequent EGFR mutations in brain metastases of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer Is Rare

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1791-9

10.1007/S00280-011-1791-9

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22130585